Novartis AG (NVS) has been the key focus due its potential for strong growth through 2029 as outlined by TD Cowen. The company's stock has outperformed the market, making big moves reported by Swiss Stocks and boosting shareholder value. Following a 17.5% rise and progress in its pipeline in 2025, shares remain attractive for investors. Crisis hit as generics negatively impacted Novartis’ Heart drug causing shares to fall. Nevertheless, other developments such as FDA’s approval of Novartis' gene replacement treatment for SMA, acquisition of Regulus Therapeutics, and $12 billion biotech deal for U.S firm Avidity Biosciences boosted the stock's momentum and value. The company has shown solid earnings mirroring its strength as a business, despite disagreements like Goldman Sachs tagging the stock as overvalued. Novartis had to maintain its Hold rating through CEO transitions, and it's shares softened premarket even as it raised outlook and sales guidance for key cancer drugs. There are a lot of room for Novartis’ growth despite hitting new share price high in 2025. TD Cowen reiterates hold rating with $140 price target while Morgan Stanley upgraded Novartis to overweight. In deals, Novartis acquired Tourmaline Bio for $1.4 billion and signed a $5.7B licensing agreement with Monte Rosa.
Novartis Stocks News Analytics from Thu, 15 May 2025 07:00:00 GMT to Sat, 29 Nov 2025 18:17:41 GMT -
Rating 4
- Innovation 3
- Information 8
- Rumor 0
